SV2010003469A - DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK ASI AS THE COMPOSITIONS METHODS OF USE AND PREPARATION OF THE SAME - Google Patents

DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK ASI AS THE COMPOSITIONS METHODS OF USE AND PREPARATION OF THE SAME

Info

Publication number
SV2010003469A
SV2010003469A SV2010003469A SV2010003469A SV2010003469A SV 2010003469 A SV2010003469 A SV 2010003469A SV 2010003469 A SV2010003469 A SV 2010003469A SV 2010003469 A SV2010003469 A SV 2010003469A SV 2010003469 A SV2010003469 A SV 2010003469A
Authority
SV
El Salvador
Prior art keywords
arilamino
inhibitors
mek
sulfonamids
polymorphes
Prior art date
Application number
SV2010003469A
Other languages
Spanish (es)
Inventor
Stuart Dimock
Barry Quart
Jeffrey Miner
Jean-Luc Girardet
Colin Edward Rowlings
Jean-Micahel Vernier
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2010003469(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of SV2010003469A publication Critical patent/SV2010003469A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

ESTA INVENCIÓN SE RELACIONA CON COMPUESTOS N-(2-ARILAMINO) ARIL SULFONAMIDA QUE SON INHIBIDORES DE MEK INCLUYENDO FORMAS POLIMÓRFICAS CRISTALINAS QUE EXHIBEN UN PERFIL DE DIFRACCIÓN DE RAYOS X EN POLVO ESPECÍFICO Y/O UN PERFIL DE CALORIMETRÍA DIFERENCIAL DE BARRIDO ESPECÍFICO. ESTA INVENCIÓN TAMBIÉN SE RELACIONA CON COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DESCRITOS Y MÉTODOS DE USO DE LOS COMPUESTOS Y COMPOSICIONES DESCRITOS, INCLUYENDO EL USO EN EL TRATAMIENTO Y/O PREVENCIÓN DE CÁNCER, ENFERMEDADES HIPERPROLIFERATIVAS Y CONDICIONES INFLAMATORIAS. LA INVENCIÓN TAMBIÉN SE RELACIONA CON MÉTODOS PARA OBTENER LOS COMPUESTOS Y COMPOSICIONES QUE SE DESCRIBENTHIS INVENTION IS RELATED TO N- (2-ARILAMINO) ARIL SULFONAMIDA COMPOUNDS THAT ARE INHIBITORS OF MEK INCLUDING CRYSTALLINE POLYMORPHIC FORMS THAT DISPLAY A SPECIFIC POWDER X-RAY DIFFECTION PROFILE AND / OR A SPECIFIC DIFFERENCE. THIS INVENTION IS ALSO RELATED TO PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THE DESCRIBED COMPOUNDS AND METHODS OF USE OF THE DESCRIBED COMPOUNDS AND COMPOSITIONS, INCLUDING THE USE IN THE TREATMENT AND / OR PREVENTION OF CANCER, HYPERTROLLING INFRASTRUCTURES AND INFRASTRUCTURES. THE INVENTION IS ALSO RELATED TO METHODS TO OBTAIN THE COMPOUNDS AND COMPOSITIONS THAT ARE DESCRIBED

SV2010003469A 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK ASI AS THE COMPOSITIONS METHODS OF USE AND PREPARATION OF THE SAME SV2010003469A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446608P 2008-03-06 2008-03-06
US3446408P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14

Publications (1)

Publication Number Publication Date
SV2010003469A true SV2010003469A (en) 2010-04-30

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003469A SV2010003469A (en) 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK ASI AS THE COMPOSITIONS METHODS OF USE AND PREPARATION OF THE SAME

Country Status (23)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20140098185A (en)
CN (2) CN103479604B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA032294B1 (en)
EC (1) ECSP109910A (en)
HK (1) HK1147396A1 (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2720671A1 (en) * 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
BR122021020475B1 (en) * 2008-09-09 2022-06-07 F. Hoffmann-La Roche Ag Acyl sulfonamide polymorphs, their use, their preparation process and pharmaceutical composition that comprises them
PT2331136T (en) 2008-09-26 2018-03-27 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
EP2405908B1 (en) 2009-03-11 2016-12-21 Ardea Biosciences, Inc. Pharmaceutical combination of rdea119/bay 869766 and gemcitabine for the treatment of specific cancers
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
CA2777304A1 (en) * 2009-10-21 2011-04-28 Marion Hitchcock Substituted benzosulphonamides
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
NZ618062A (en) * 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
PE20140580A1 (en) * 2011-05-27 2014-06-01 Bayer Ip Gmbh CHIRAL SYNTHESIS OF N- {3,4-DIFLUORO-2 - [(2-FLUORO-4-IODOPHENYL) AMINO] -6-METOXYPHENYL} -1- [2,3-DIHYDROXY-PROPYL] CYCLOPROPANOSULPHONAMIDES
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
EA201401353A1 (en) * 2012-05-31 2015-05-29 Байер Фарма Акциенгезельшафт BIOMARKERS TO DETERMINE AN EFFECTIVE RESPONSE RESPONSE TO THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
CN110354132A (en) 2012-06-04 2019-10-22 药品循环有限责任公司 The crystalline form of bruton's tyrosine kinase inhibitor
US9238627B2 (en) * 2012-10-19 2016-01-19 Array Biopharma, Inc. Preparation of and formulation comprising a MEK inhibitor
WO2014071183A1 (en) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US11197896B2 (en) 2014-08-25 2021-12-14 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof
TW202315634A (en) 2015-03-03 2023-04-16 美商製藥公司 Pharmaceutical formulations of a bruton’s tyrosine kinase inhibitor
CN110799191B (en) * 2017-06-16 2023-05-26 贝塔制药有限公司 Pharmaceutical formulations of N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide and salts thereof
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
KR100336699B1 (en) * 1992-08-25 2002-05-13 윌리암스 로저 에이 Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
SK9822001A3 (en) * 1999-01-13 2002-08-06 Warner Lambert Co 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CA2461227C (en) * 2001-09-24 2012-05-15 Jessie L.-S Au Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
AU2003251942A1 (en) * 2002-07-17 2004-02-02 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
JP2005535688A (en) * 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of alkylphosphocholines in combination with antitumor drugs
BRPI0607537A2 (en) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd nanoparticulate quinazoline derivative formulations
WO2006115154A1 (en) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. Crystal polymorphism of 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid hydrochloride
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd New crystal of piperacillin sodium-1 hydrate and method for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
DOP2010000045A (en) 2010-10-31
ECSP109910A (en) 2010-04-30
EP2184984A4 (en) 2013-07-24
EA201000268A1 (en) 2010-08-30
CO6470808A2 (en) 2012-06-29
JP2010535232A (en) 2010-11-18
AP2817A (en) 2013-12-31
MA31881B1 (en) 2010-12-01
CN101808516A (en) 2010-08-18
TN2010000049A1 (en) 2011-09-26
EA020624B1 (en) 2014-12-30
PH12015501914A1 (en) 2017-07-31
NZ582929A (en) 2012-03-30
KR20150091434A (en) 2015-08-10
AP2010005134A0 (en) 2010-02-28
IL203296A (en) 2017-06-29
HK1147396A1 (en) 2011-08-12
JP2017125021A (en) 2017-07-20
HN2010000203A (en) 2012-11-19
KR20100092424A (en) 2010-08-20
AU2008282338B2 (en) 2015-02-12
MX2010001244A (en) 2010-08-31
KR20140098185A (en) 2014-08-07
CA2693390C (en) 2017-01-17
CR11244A (en) 2010-05-20
JP6309880B2 (en) 2018-04-11
CA2693390A1 (en) 2009-02-05
AU2008282338A1 (en) 2009-02-05
CN101808516B (en) 2013-08-28
EA201400552A1 (en) 2014-09-30
BRPI0815659A2 (en) 2014-09-30
JP2015078199A (en) 2015-04-23
WO2009018233A1 (en) 2009-02-05
EA032294B1 (en) 2019-05-31
CN103479604B (en) 2016-08-10
EP2184984A1 (en) 2010-05-19
AU2015200390B2 (en) 2017-02-23
CN103479604A (en) 2014-01-01

Similar Documents

Publication Publication Date Title
SV2010003469A (en) DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK ASI AS THE COMPOSITIONS METHODS OF USE AND PREPARATION OF THE SAME
ECSP077268A (en) RAPAMYCIN POLYMORPH II AND THE USES OF THE SAME
DOP2006000193A (en) ISOINDOL-IMIDA COMPOUNDS AND COMPOSITIONS INCLUDING THEM AND METHODS FOR USE
ECSP088749A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
GT201000061A (en) DERIVATIVES OF URACILO OR TIMINA FOR THE TREATMENT OF HEPATITIS C
ECSP10010415A (en) NEW COMPOUNDS THAT ARE ERK INHIBITORS
UY29601A1 (en) SUBSTITUTED ARILPIRAZOLES
HN2012001162A (en) TRIAZOLOPIRIDINS
CL2019001993A1 (en) Selective inhibitors of jak1.
CL2008000946A1 (en) COMPOUNDS DERIVED FROM PIRROLOPIRIMIDINA, INHIBITORS OF CIANASA JAK3; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF REPLACEMENT OF TRANSPLANTS, AUTOIMMUN DISEASES
ECSP10010722A (en) ORGANIC COMPOUNDS
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
UY32611A (en) 1-CYANOETHYLETHYCLIC CARBOXAMIDE SUBSTITUTED COMPOUNDS 750
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
UY29767A1 (en) BENZOTIAZOLONAS DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
UY28708A1 (en) REPLACED HETEROCICLES AND USES OF THE SAME
CU20090058A7 (en) PIRAZOLINE COMPOUNDS AND THEIR USE AND PHARMACEUTICAL COMPOSITIONS
ECSP088584A (en) NEW DERIVATIVES OF BENZIMIDAZOL AS INHIBITORS OF VANILLOID RECEIVER 1 (VRL)
GT201000047A (en) IMPROVEMENTS IN ORGANIC COMPOUNDS OR RELATED TO THE SAME
ECSP11011344A (en) NEW ANTIBODIES ANTI-? 5? 1 AND ITS USES
UY28670A1 (en) SUBSTITUTED ARILPIRAZOLES
GT200600123A (en) DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR
ECSP13012716A (en) COMPOUNDS AND ITS USES
CO2020004977A2 (en) Bicyclic compounds for use as ripi kinase inhibitors
CO2018004572A2 (en) Human plasma kallikrein inhibitors